Stifel raised the firm’s price target on GE HealthCare to $102 from $100 and keeps a Buy rating on the shares. GE Healthcare received “welcome news” on Friday night from the FDA with approval of the the Flurpiridaz radiopharmaceutical, a first-of-its-kind myocardial perfusion imaging positron emission tomography, or PET, radiopharmaceutical available as an “individual dose” made-in-advance versus today’s on-site dose manufacturing, the analyst tells investors. The analyst says the firm’s physician due diligence leads it to believe that Flurpiridaz offers meaningful clinical improvements compared to other MPI radiopharmaceuticals; that uptake among existing U.S. cardiac PET centers should happen quickly; and that Flurpiridaz availability should expand U.S. cardiac PET access broadly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare announces FDA approval of Flyrcado injection PET radiotracer
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Starbucks upgraded, Hershey downgraded: Wall Street’s top analyst calls
- GE HealthCare downgraded to Sell from Neutral at UBS
- GE HealthCare price target raised to $97 from $86 at BofA